Innoviva Inc Dossier - Source-backed chat

Innoviva Inc

INVANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.56

Intrinsic Value $20.91median of 4 methods · middle span $20-$22based on filings through 30 Jun 2026

Market Price $20.55Price as of 1 Oct 2026

Near fair valueIntrinsic value is 2% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1.5B

Enterprise Value $1.2B

Shares Outstanding 72.2M diluted

Moat Rating Wide

Next Earnings Date4 Nov 2026

Last ex-dividend8 Sep 2015

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Innoviva is successfully executing a strategic transformation from a single-source respiratory royalty vehicle into a diversified biopharmaceutical platform. The company's investment narrative is anchored by three pillars: a highly resilient legacy respiratory royalty stream from GSK, a rapidly growing specialty therapeutics platform (IST) focused on critical care and infectious diseases, and a valuable portfolio of strategic healthcare investments. With the recent FDA approval of NUZOLVENCE (zoliflodacin) and the commercial rollout of ZEVTERA, Innoviva is well-positioned to offset the upcoming patent cliffs of its legacy assets. Trading at a discount relative to its biotech peers, the stock offers asymmetric upside potential as the market begins to recognize the intrinsic value of its newly built operating business and strategic assets.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$18.00

Mean target$35.00

High · most bullish analyst$46.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential commercialization failures, slower-than-expected hospital adoption of newly launched antibiotics, or intense generic erosion of the legacy respiratory portfolio. If GSK de-prioritizes the partnered products or if clinical trials for strategic investments face delays or negative outcomes, the market may discount the operating business, leaving the stock reliant solely on the declining royalty stream.

Base CaseCentral scenario

The base case assumes steady commercial execution of the IST portfolio, with US net product sales on track to meet or exceed the $150 million target for 2026. Resilient royalty inflows from GSK continue to provide robust cash flow, supporting the active $125 million share buyback program. The commercial launch of NUZOLVENCE in H2 2026 proceeds smoothly, and strategic assets like Armata and Syndeio achieve their clinical milestones, driving a gradual market re-rating.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Resilient legacy royalty portfolio (Relvar/Breo and Anoro Ellipta) providing stable, high-margin cash flows to fund diversification.
Rapidly expanding specialty therapeutics platform (IST) with multiple newly approved or launched products (XACDURO, ZEVTERA, NUZOLVENCE) targeting high-unmet-need infectious diseases.
Valuable portfolio of strategic healthcare investments (valued at over $600 million) offering significant asymmetric clinical upside.
Strong balance sheet with substantial cash resources ($603.1 million as of Q1 2026) and an active $125 million share repurchase program.

Key Investment Risks

High concentration risk and reliance on GSK's commercial execution for the core royalty revenue stream.
Upcoming patent cliffs for legacy respiratory assets in the 2029-2030 timeframe.
Commercialization and execution risks associated with launching novel antibiotics in a highly challenging hospital and infectious disease market.
Clinical and regulatory risks inherent in development-stage strategic investments.

Thesis Invalidation Triggers

A sharp, unexpected decline in GSK respiratory product sales or rapid generic erosion prior to 2029.
Failure of NUZOLVENCE to secure commercial traction or establish effective distribution partnerships in H2 2026.
Negative clinical trial readouts or regulatory setbacks for key strategic assets like Armata or Syndeio.
Material capital allocation missteps or value-destructive acquisitions that deplete the company's cash reserves.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.